Quinazoline compound for inducing degradation of G12D mutant KRAS protein
US12384794B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 14, 2022 |
| Grant date | Aug 12, 2025 |
| Priority date | — |
| Expiry date | Oct 20, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
[Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer.[Means for resolution] The present inventors have studied about a compound that is useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a quinazoline compound has an excellent degradation-inducing action on a G12D mutant KRAS protein and a G12D mutant KRAS inhibition activity and can be used as a therapeutic agent for pancreatic cancer, thus completing the present invention. The quinazoline compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.